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Background: Several studies have shown an association between chronic obstructive pulmonary 
disease (COPD) and cognitive impairment. These studies have been limited by methodologi-
cal issues such as diagnostic uncertainty, cross-sectional design, small sample size, or lack of 
appropriate referent group. This study aimed to elucidate the association between COPD and 
the risk of cognitive impairment compared to referent subjects without COPD. In patients with 
established COPD, we evaluated the impact of disease severity and impairment of respiratory 
physiology on cognitive impairment and the potential mitigating role of oxygen therapy.
Methods: We used the Function, Living, Outcomes and Work (FLOW) cohort study of adults 
with COPD (n = 1202) and referent subjects matched by age, sex, and race (n = 302) to study 
the potential risk factors for cognitive impairment among subjects with COPD. Cognitive 
impairment was defined as a Mini-Mental State Exam score of ,24 points. Disease severity 
was using Forced Expiratory Volume in one second (FEV1); the validated COPD Severity 
Score; and the BMI (Body Mass Index), Obstruction, Dyspnea, Exercise Capacity (BODE) 
Index. Multivariable analysis was used to control for confounding by age, sex, race, educational 
attainment, and cigarette smoking.
Results: COPD was associated with a substantive risk of cognitive impairment compared to 
referent subjects (odds ratio [OR] 2.42; 95% confidence interval [CI] 1.043–6.64). Among 
COPD patients, none of the COPD severity measures were associated with the risk of cognitive 
impairment (P . 0.20 in all cases). Low baseline oxygen saturation was related to increased 
risk of cognitive impairment (OR for oxygen saturation # 88% (OR 5.45; 95% CI 1.014–29.2; 
P = 0.048). Conversely, regular use of supplemental oxygen therapy decreased the risk for 
cognitive impairment (OR 0.14; 95% CI 0.07–0.27; P , 0.0001).
Conclusion: COPD is a major risk factor for cognitive impairment. Among patients with 
COPD, hypoxemia is a major contributor and regular use of home oxygen is protective. Health 
care providers should consider screening their COPD patients for cognitive impairment.
Keywords: chronic obstructive pulmonary disease
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by the irreversible 
loss of lung function. Although COPD has been traditionally considered as a disease 
primarily affecting the lungs, its systemic effects have been increasingly recognized with 
diverse manifestations involving body systems distant from the lung.1,2 The brain, in 
  particular, may be vulnerable to the systemic effects of COPD.3–8 Several features of the 
disease may contribute to impaired cognitive function, including hypoxemia and comor-
bid cardiovascular disease.7–9 In addition, COPD may lead patients to curtail their physical 
activity which may, in turn, further increase the risk of cognitive impairment.10International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Although there is a plausible link between COPD and 
cognitive impairment, the existing literature is limited by 
methodological issues such as diagnostic uncertainty, cross-
sectional design, small sample size, or lack of appropriate 
referent group.11–14 In a large cohort study of COPD, we 
aimed to elucidate the impact of COPD on the risk of cog-
nitive impairment compared to a matched referent group 
without disease. Among patients with established COPD, 
we evaluated the impact of disease severity and impairment 
of respiratory physiology on cognitive impairment and the 
potential mitigating role of oxygen therapy.
Methods
recruitment of the cohort  
and referent subjects
The current study is a matched case-referent analysis con-
ducted within the Function, Living, Outcomes, and Work 
(FLOW) study of COPD. The FLOW study is an ongoing 
prospective cohort study of adult members of an integrated 
health care delivery system with a physician’s diagnosis 
of COPD with an accompanying matched control group. 
Recruitment methods have been previously reported in 
detail.1,15–17 We recruited a cohort of 1,202 Kaiser Perma-
nente Medical Care Program (KPMCP) members who were 
recently treated for COPD using a validated algorithm based 
both on health care utilization and pharmacy dispensing for 
COPD.18 A control group of 302 subjects without COPD 
were recruited who were matched by age, sex, and race to 
the cohort members. Spirometry confirmed that none of the 
controls met Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) criteria for COPD. At baseline assessment, 
we conducted structured telephone interviews that ascer-
tained sociodemographic characteristics, COPD clinical 
history, and health status.1,15,16 Research clinic visits included 
spirometry, other physical assessments, and cognitive testing. 
The study was approved both by the University of California, 
San Francisco Committee on Human Research and the Kaiser 
Foundation Research Institute’s institutional review board 
and all participants provided written informed consent.
structured telephone interviews
All subjects (COPD subjects and non-COPD referents) 
underwent 30–40 minute structured telephone interviews 
that ascertained sociodemographic characteristics, cigarette 
smoking, health status, and home oxygen use. As in our 
previous studies, we defined educational attainment as high 
school or less, some college, or college/graduate degree.19 
Race-ethnicity was categorized as white non-Hispanic, 
  African American, Asian/Pacific Islander, Hispanic, or 
other.19 Cigarette smoking was measured using questions 
developed for the National Health Interview Survey (NHIS) 
and was defined as current smoking, past smoking, or never 
smoked.20 We assessed comorbid cardiovascular conditions 
using survey items modified from the NHIS.21 These include a 
reported physician’s diagnosis of coronary artery disease, con-
gestive heart failure, or stroke based on our previous work.1
Assessment of pulmonary physiology
Baseline oxygen saturation was measured at rest in the seated 
position using the Nellcor N-180 (Covidien-Nellcor, Boulder, 
CO). Most subjects were measured on room air; 61 subjects 
had oxygen saturation measured on their prescribed supple-
mental oxygen (range 1–4 liters/minute).
To measure pulmonary function, we conducted spiro-
metry according to American Thoracic Society (ATS) 
Guidelines.22,23 We used the EasyOne™ Frontline spirometer 
(ndd Medical Technologies, Chelmsford, MA, USA), which 
is known for its reliability, accuracy, and durability and has 
been widely used in epidemiologic research.24,25 Because 
research clinic examinations were conducted by trained 
nonmedical personnel, we did not administer bronchodila-
tors for study purposes. However, 90% of subjects had taken 
their own short-acting bronchodilator within 4 hours of 
spirometry or had taken a long-acting bronchodilator earlier 
in the same day.
Measurement of COPD severity
We used a combined approach to measure COPD severity. 
We used a disease-specific COPD severity score that we had 
previously developed and validated for use in epidemiologic 
and outcomes research.26,27 Based on survey responses, the 
COPD severity score is comprised of five overall aspects of 
COPD severity: respiratory symptoms, systemic corticoster-
oid use, other COPD medication use, previous hospitaliza-
tion or intubation for respiratory disease, and home oxygen 
use. Each item was weighted based on clinical aspects of 
the   disease and its expected contribution to overall COPD 
severity. Possible total scores range from 0 to 35, with higher 
scores reflecting more severe COPD.
We also used the validated BMI (Body Mass Index), 
Obstruction, Dyspnea, Exercise Capacity (BODE) Index, 
which is a multi-modal measure of disease severity.28 The 
BODE Index is based on the body-mass index (B), the degree 
of airflow obstruction (O) measured by Forced Expira-
tory Volume in one second (FEV1), grade of dyspnea (D) 
assessed by the modified Medical Research Council (MRC) International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Dyspnea Scale, and exercise capacity (E) measured by the 
six-minute-walk test. Each component is assigned a specific 
score and the total score ranges from 0 to 10 points (higher 
scores indicate greater severity). The BODE index predicts 
death and other poor outcomes in COPD.28–30
Cognitive assessment
At the time of the research clinic visit, cognitive function was 
measured using the Mini-Mental State Examination, which is 
the most commonly used screening test for cognitive impair-
ment in North America.31 The 11-item instrument assesses 
orientation, recall ability, short-term memory, and arithmetic 
ability.32 It evaluates most of the main domains of cognitive 
status and has been extensively validated.31–36 We used the 
recommended cut-point score of ,24 points out of the total 
possible 30 points to indicate cognitive impairment.37
statistical analysis
Statistical analysis was conducted using SAS software, ver-
sion 9.1 (SAS Institute, Inc, Cary, NC, USA) and Stata 10 
(College Park, TX, USA). Bivariate comparisons were 
carried out using t-test for continuous variables and the 
chi-square test for categorical variables. We used logistic 
regression analysis to examine the association between 
COPD (vs referent) and the risk of cognitive impairment, 
controlling for age, sex, race, educational attainment, and 
smoking history (past smoking and current smoking as 
indicator variables).
In the COPD cohort, we used multivariable logistic 
regression analysis to elucidate the association between 
COPD severity measures and the risk of cognitive impair-
ment. Risk estimates (ie, odds ratios) were expressed per a 
0.5 standard deviation of each predictor variable, an approxi-
mation of the minimal clinically important difference.38 
Multivariable analysis was used to control for age, sex, race, 
educational attainment, and smoking history.
We also evaluated the impact of home oxygen use on 
the risk of cognitive impairment. Because oxygen therapy is 
prescribed to patients with more severe disease, confounding 
by indication will likely bias the unadjusted results in the 
direction of no effect. We used two approaches to control 
for confounding. First, we used standard multivariable 
logistic regression. Second, we used propensity scores to 
correct for confounding by indication. Propensity scores 
were developed from a multivariable logistic regression 
model to predict home oxygen use conditional on observed 
covariates. Variables included were age, sex, race, smoking 
history, BODE Score, FEV1, baseline oxygen saturation 
(#88%), and desaturation during Six Minute Walk Test 
($4%). Area under receiver operator characteristic curve 
for this model was excellent (0.92). Multivariable logistic 
regression analysis was then used to evaluate the impact of 
home oxygen use on the risk of cognitive impairment using 
inverse probability-weighted estimators derived from the 
propensity scores to control for confounding.39
The LOWESS (locally weighted regression scatter plot 
smoother) procedure was used to graphically depict the 
relationship between oxygen saturation and the logit (ie, log 
odds) of cognitive impairment. This method fitted a flexible 
smoothed curve that did not impose a linear relationship.40
Results
Baseline characteristics of subjects  
with and without COPD
Subjects with and without COPD were similar in age, sex, 
and race-ethnicity, which reflected matching (P . 0.20 in 
all cases) (Table 1). The prevalence of lifetime smoking was 
higher among those with COPD (87%) than in the referent 
group (48%) (P , 0.0001). Persons with COPD also had 
lower educational attainment than referents.
COPD and the risk  
of cognitive impairment
The prevalence of cognitive impairment was much higher 
among COPD subjects compared to the matched referent 
group without COPD (5.5% vs 2.0%, P = 0.0051). In multi-
variable analysis, COPD was associated with a greater risk 
of cognitive impairment function even after controlling for 
age, sex, race, smoking history, and educational attainment 
(OR 2.42, 95% CI 1.043–6.64) (Table 2).
risk factors for cognitive impairment 
among subjects with COPD
Among patients with COPD, respiratory impairment, as 
measured by FEV1, was not associated with cognitive impair-
ment (Table 3). Low baseline oxygen saturation (#88%) was 
strongly related to cognitive impairment (adjusted OR 5.45; 
95% CI 1.014–29.2). A small minority of subjects (n = 61) 
used prescribed supplemental oxygen. When oxygen use 
was added to the multivariable model, low oxygen satura-
tion remained associated with a greater risk of cognitive 
impairment (OR 5.46; 95% CI 1.007–30). Figure 1 demon-
strates that the risk of cognitive impairment increases with 
decreasing oxygen saturation, but that the relationship is 
non-linear.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
266
Thakur et al
The risk of cognitive impairment was not associated with 
COPD severity as defined by either the COPD severity score or 
BODE score (Table 3). Stroke and other cardiovascular disease 
were also not related to cognitive impairment (Table 4).
home oxygen therapy and cognitive 
impairment in COPD
Home oxygen therapy was associated with a decreased 
risk of cognitive impairment among persons with COPD 
(Table 5). The unadjusted estimate, which was likely 
confounded by indication, did not exclude the ‘no effect’ 
level. In the most adjusted model, using inverse probability-
weighted estimators derived from the propensity scores to 
control for confounding, home oxygen use was strongly 
associated with a decreased risk of cognitive impairment 
(OR 0.14; 95% CI 0.01–0.27).
Discussion
COPD is often considered a disease that solely affects the 
lungs; however, its extrapulmonary effects are profound and 
disabling. Our study indicates that COPD is strongly associ-
ated with cognitive impairment in a large cohort of patients 
with a broad range of COPD severity. Resting hypoxemia 
was the single most important risk factor for cognitive 
impairment; treatment with supplemental oxygen markedly 
decreased the risk. Lung function impairment, COPD sever-
ity, and cardiovascular disease did not appear to explain the 
development of cognitive impairment in COPD.
We used a rigorous and multifaceted approach to measur-
ing COPD severity (lung function, COPD Severity Score, and 
BODE Index). Despite this approach, we found no impact of 
these indicators of disease severity on the risk of cognitive 
impairment. This differs from some previous work,41 but is 
similar to other studies that found no association between 
disease severity and cognitive impairment.42 Our results 
reveal a disconnect between global measures of COPD 
severity, which were not related to cognitive impairment, and 
decreased resting oxygenation, which was strongly associated 
with decreased cognitive function.
The specific role of cardiovascular comorbidities as a 
risk factor for cognitive impairment in COPD is difficult to 
ascertain as both conditions share risk factors (eg, smoking) 
and COPD patients may be predisposed to cardiovascular 
events.18 When cardiovascular comorbidities were evaluated 
as a risk factor for cognitive impairment, no association was 
found among the COPD cohort. The point estimate for car-
diovascular disease was elevated, however, in the unadjusted 
analysis, so lack of statistical power may be one explanation 
Table 1 Baseline characteristics of FLOW cohort of COPD vs referent subjects
Characteristic COPD (n = 1,202) Referents (n = 302) P-value
Age in years, mean (sD) 58.2 (6.2) 58.5 (6.2) 0.50
Female, n (%) 691 (57.4%) 185 (61%) 0.23
race/ethnicity, n (%) 0.96
  White, non-hispanic 810 (67%) 200 (66%)
  African-American 206 (17%) 57 (19%)
  Asian/Pacific Islander 35 (3%) 8 (3%)
  hispanic 111 (9%) 28 (9%)
  Other  40 (3%) 9 (3%)
educational attainment, n (%) ,0.0001
  high school or less 352 (29%) 42 (14%)
  some college 524 (44%) 95 (31%)
  College/graduate degree 326 (27%) 165 (55%)
smoking status, n (%) ,0.0001
  never smoked 165 (13%) 158 (52%)
  Current smoker 393 (33%) 12 (4%)
  ex-smoker 644 (54%) 132 (44%)
Abbreviations: COPD, chronic obstructive pulmonary disease; FLOW, Function, Living, Outcomes and Work; sD, standard deviation.
Table 2 COPD and the risk of cognitive impairment
Comparison Unadjusted 
OR (95% CI)
Controlling for age, sex, race, educational  
attainment, and smoking history OR (95% CI)
referent group 1.0 1.0
COPD  2.86 (1.34–7.46)  2.42 (1.043–6.64)
Abbreviations: CI, confidence interval; OR, odds ratio.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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  disease management. More broadly, cognitive impairment 
may create difficulties with performing daily activities, espe-
cially those that involve memory or complex reasoning.43 It 
is likely that cognitive impairment has major effects on many 
aspects of patient functioning and health status.
The MMSE is a widely used measure of cognitive impair-
ment but it is not sensitive for mild cognitive dysfunction.44,45 
Consequently, our methods could have missed cases of mild 
cognitive impairment. It remains possible, therefore, that 
COPD severity could predict milder degrees of cognitive 
dysfunction. A future analysis of cognitive impairment using 
a detailed neuropsychologic battery of tests is required to 
evaluate milder cognitive impairment in COPD.
Our study is subject to several other limitations. Because 
our primary study focus was development of disability in 
COPD, we enrolled younger patients (45–65 years). Conse-
quently, our study may underestimate the impact of COPD 
on cognitive impairment in older patients. Misclassification 
Table  3  relationship  between  COPD  severity  and  cognitive 
impairment
Disease severity measure Risk of cognitive impairment
Unadjusted Multivariable
OR (95% CI) OR (95% CI)†
Forced expiratory volume in 1 
second*
0.97 (0.85–1.11) 
P = 0.63
0.93 (0.79–1.09) 
P = 0.35
Baseline oxygen saturation 
#88%‡
4.41 (0.92–21) 
P = 0.064
5.45 (1.014–29.2) 
P = 0.048
BODe score*  1.13 (1.002–1.27) 
P = 0.046
1.08 (0.95–1.23) 
P = 0.25
COPD severity score* 1.08 (0.94–1.23) 
P = 0.28
1.03 (0.90–1.17) 
P = 0.66
*odds ratio per ½ standard deviation decrement.
†separate multivariable logistic regression analysis for each severity measure plus 
age, sex, race, educational attainment, and smoking history.
‡61  subjects  had  oxygen  saturation  measured  on  supplemental  oxygen  (range 
1–4 liters/minute). When oxygen use was added to the multivariable model, low 
oxygen saturation remained associated with a greater risk of cognitive impairment 
(Or 5.46; 95% CI 1.007–30; P = 0.049). In additional analysis, oxygen flow rate   
(no oxygen, flow = 0 liters/minute) was added to the multivariable model with minimal 
impact on the results (Or 5.44; 95% CI 1.008–29; P = 0.049).
Abbreviations: BODe, BMI (Body Mass Index), Obstruction, Dyspnea, exercise 
Capacity; CI, confidence interval; COPD, chronic obstructive pulmonary disease; OR, 
odds ratio.
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Figure 1 relationship between resting oxygen saturation and the risk of cognitive 
impairment. Oxygen saturation was measured using pulse oximetry. The LOWess 
(locally weighted regression scatter plot smoother) procedure was used to graphically 
depict the relationship between oxygen saturation and the logit (ie, log odds) of 
cognitive impairment. This method fitted a flexible smoothed curve that did not 
impose a linear relationship.
Table  4  Cardiovascular  disease  and  the  risk  of  cognitive 
impair-ment in COPD
Cardiovascular disease Risk of cognitive impairment
Unadjusted Multivariable
OR (95% CI) OR (95% CI)†
stroke (n = 68; 4.5%) 0.81 (0.25–2.66) 
P = 0.73
0.78 (0.23–2.61) 
P = 0.68
Other cardiovascular disease 
(n = 841; 56%)* 
1.57 (0.92–2.69) 
P = 0.10
1.30 (0.74–2.31) 
P = 0.36
*hypertension, coronary artery disease, or congestive heart failure.
†Multivariable logistic regression analysis including age, sex, race, educational 
attainment, and smoking history.
Abbreviations: CI, confidence interval; OR, odds ratio.
Table 5 home oxygen use and the risk of cognitive impairment 
in COPD
Statistical model Risk of cognitive impairment 
OR (95% CI)
Unadjusted 0.74 (0.26–1.71) 
P = 0.53
Multivariable model*  0.40 (0.11–1.17) 
P = 0.11
Multivariable model (propensity  
score adjusted)†
0.14 (0.07–0.27) 
P , 0.0001
*Multivariable logistic regression analysis including home oxygen use plus age, sex, 
race, educational attainment, smoking history, baseline oxygen saturation, BODe 
score, COPD severity score, FeV1, and height.
†Multivariable model including inverse probability-weighted estimators, which were 
derived from propensity scores. Propensity scores were developed from a separate 
multivariable  logistic  regression  model  to  predict  home  oxygen  use.  Variables 
included were age, sex, race, smoking history, BODe score, FeV1, and baseline 
oxygen saturation (#88%). Area under receiver operator characteristic curve for 
model was 0.92. see Methods for more details.
Abbreviations: BODe, BMI (Body Mass Index), Obstruction, Dyspnea, exercise Capacity; 
CI, confidence interval; CI, confidence interval; COPD, chronic obstructive 
pulmonary disease; FeV1, Forced expiratory Volume in one second; Or, odds ratio.
for this lack of effect. Controlling for covariates, such as 
smoking, reduced the effect estimate, so that any association 
between cardiovascular disease and cognitive impairment 
may be mediated by smoking and other factors.
Cognitive impairment may interfere with patients’ ability 
to adhere to their medication regimen, adjust their medica-
tions in response to respiratory symptoms, and perform 
other aspects of self-management. Given that many of the 
medications for COPD are self-activated, even mild degrees 
of cognitive impairment could have significant effects on International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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of COPD could also have occurred. Our COPD definition 
required concomitant treatment with COPD medications 
to increase the specificity of our definition. In addition, all 
patients had a physician diagnosis of COPD and reported 
having the condition. The lifetime smoking prevalence was 
similar to that in other population-based epidemiologic stud-
ies of COPD, supporting the diagnosis of COPD rather than 
asthma.46,47 We also previously demonstrated the validity of 
our approach using medical record review.18 Nonetheless, 
we acknowledge this potential limitation.
Another limitation is the small proportion of subjects 
who were using home oxygen. Consequently, the confidence 
intervals around our estimates of the effectiveness of oxygen 
for preventing cognitive impairment are wide in some cases. 
As the FLOW cohort continues longitudinal follow-up, we 
will further evaluate the impact of oxygen therapy on cogni-
tive function.
COPD is a multisystem disease with extrapulmonary 
sequelae. It is strongly associated with an increased risk of 
cognitive impairment, especially among hypoxemic patients. 
Clinicians should evaluate their COPD patients for cognitive 
impairment in order to identify those who may benefit from 
interventions such as medication assistance or supplemental 
oxygen therapy. Future research should use detailed neurop-
sychological testing to carefully evaluate multiple cognitive 
domains among subjects with a broad range of ages and 
disease severity.
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